Gnant, Michael <br/><br/>
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  03 2019 
 - 339-351 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30862-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aromatase Inhibitors--administration & dosage<br/>Bone Density--drug effects<br/>Breast Neoplasms--drug therapy<br/>Denosumab--administration & dosage<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Middle Aged<br/>Postmenopause--drug effects<br/>Proportional Hazards Models<br/>Receptor, ErbB-2--genetics<br/>Receptors, Estrogen--genetics<br/>Receptors, Progesterone--genetics